Search results
In areas that are highly endemic for Lyme disease, a single prophylactic dose of doxycycline (200 mg for adults or 4.4 mg/kg for children of any age weighing less than 45 kg) may be used to reduce the risk of acquiring Lyme disease after a high-risk tick bite. Benefits of prophylaxis may outweigh risks when all of the following circumstances ...
Lyme disease is caused by bacteria called Borrelia. Ticks can attach to any part of the human body but prefer hard-to-see areas such as the groin, armpits, and scalp. In most cases, the tick must be attached and fill with blood before Lyme disease bacteria can be transmitted.
Apr 21, 2023 · Lyme disease, or borreliosis, is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of an infected blacklegged deer tick. It is the most common tickborne infectious disease in the United States.
Sep 1, 2023 · Lyme disease symptoms. It’s important to understand why Lyme infections can lead to such disparate outcomes, Mead said. Symptoms can include: Skin rash. Fever. Chills. Swollen lymph nodes ...
Early Lyme Disease Treatment. ILADS doctors are likely to recommend more aggressive and longer antibiotic treatment for patients. They may, for instance, treat “high risk” tick bites where the tick came from an endemic area, was attached a long time, and was removed improperly. They may treat a Lyme rash for a longer period of time than the ...
Nov 30, 2020 · This evidence-based clinical practice guideline for the prevention, diagnosis, and treatment of Lyme disease was developed by a multidisciplinary panel representing the Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR). The scope of this guideline includes ...
Aug 11, 2022 · Clinical trials of new vaccines for Lyme disease are currently underway. Valneva and Pfizer have developed a Lyme disease vaccine candidate, VLA15, that is currently in Phase 3 human trials. VLA15 is a multivalent, protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia.
